Saturday 17 October 2026
Export NSRX’s income statement to Excel — free account
Nasus Pharma Ltd.
NSRX Healthcare Drug Manufacturers General
Insiders bought in the last twelve months.
3.18
0.01
+0.32%
Follow NSRX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 5.90 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 9.99 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 2 | 7 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | (1) | (2) | (6) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | (1) | (2) | (6) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | (0.15) | (0.22) | (0.73) | |||||
| Cash flow | — | — | — | — | — | — | — | (0.15) | (0.09) | (0.61) | |||||
| Capex | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | — | (0.15) | (0.09) | (0.62) | |||||
| Book value | — | — | — | — | — | — | — | (0.55) | (0.46) | 0.35 | |||||
| Shares, m | — | — | — | — | — | — | — | 7 | 7 | 8 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (1) | (1) | (5) | ||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | |||||
| Free cash flow | — | — | — | — | — | — | — | (1) | (1) | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | (4) | (3) | 3 | ||||
| Total debt | — | — | — | — | — | — | — | 2 | 2 | — | |||||
| Net debt | — | — | — | — | — | — | — | 2 | 1 | (1) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (4) | (3) | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (263.91) | (204.72) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | (207.52) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 43.72 | 2,637.84 | |||||
Negative figures in brackets.
Charts ten years each
Nasus Pharma Ltd. vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SNY Sanofi | $96.0B | 21.3× | — | +17.35% (above 0%: growing) | −90.76% (below 0%: shrinking) | −45.06% (below 0%: shrinking) | 75.47% | 17.48% | Compare |
| BIIB Biogen Inc. | $34.8B | 41.0× | 31.5× | +3.42% (above 0%: growing) | −84.76% (below 0%: shrinking) | +103.28% (above 0%: growing) | 71.60% | 5.52% | Compare |
| OGN Organon & Co. | $3.6B | 17.4× | 5.2× | −2.26% (below 0%: shrinking) | −26.79% (below 0%: shrinking) | −82.97% (below 0%: shrinking) | 54.36% | 20.67% | Compare |
| GRFS Grifols, S.A. | $2.0B | 8.5× | — | +5.76% (above 0%: growing) | +466.92% (above 0%: growing) | +300.52% (above 0%: growing) | 36.47% | 14.76% | Compare |
| AMRN Amarin Corporation PLC | $244.4M | — (loss-making) | — (loss-making) | −41.97% (below 0%: shrinking) | n/m | −60.23% (below 0%: shrinking) | 35.51% | (28.45%) | Compare |
| NSRX Nasus Pharma Ltd. | $37.1M | — | — | — | — | −486.98% (below 0%: shrinking) | — | — | |
| MIRA MIRA Pharmaceuticals, Inc. | $27.7M | — (loss-making) | — | — | n/m | −50.76% (below 0%: shrinking) | — | 0.00% | Compare |
| SCLX Scilex Holding Company | $19.8M | — (loss-making) | — (loss-making) | −22.78% (below 0%: shrinking) | n/m | −203.76% (below 0%: shrinking) | 51.88% | (385.02%) | Compare |
| MDCX Medicus Pharma Ltd | $6.3M | — (loss-making) | — | — | n/m | −27.70% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $1.1B | 19.3× | — | +0.58% | −55.77% | −47.91% | 53.12% | 2.76% |
Nasus Pharma Ltd. (NSRX) key facts
- Concern: Nasus Pharma Ltd. reported a net loss of $5.8 million, or a loss of $0.73 per share, for fiscal 2025.
- Nasus Pharma Ltd. (NSRX) is a Drug Manufacturers General company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, NSRX traded at $3.18, a market capitalization of $37.1 million.
- Return on equity was 2,637.8% and debt-to-equity 0.00.